The Milner Therapeutics Institute was established in 2015 with a vision of building close collaborative interactions between academia and industry to help transform groundbreaking science into therapies. The Institute opened on the Cambridge Biomedical Campus in 2019. The outreach programme of the Institute is through the Milner Therapeutics Consortium and the Affiliated Company Partnership scheme. Working closely with the CRUK Cambridge Centre, the Milner Institute provides opportunities for researchers to engage with our industry partners and initiate pre-clinical research collaborations.
The Milner Therapeutics Institute houses academia, industry and start-ups side by side on the bench, creating an innovative hub for therapeutic research. The Institute is also home to a number of strategic units and academics in residence, including the AstraZeneca-CRUK Functional Genomics Centre(link is external), Dr Manav Pathania(link is external), the bioincubator Frame Shift supporting start-up companies, and the start-up accelerator Start Codon(link is external). These groups, with their knowledge and expertise, contribute significantly to the unique cross-sector environment the MTI is building.
The Milner Therapeutics Consortium has been active since June 2015 and is based on a research agreement signed by three academic centres in Cambridge and 11 pharmaceutical companies: the University of Cambridge, the Wellcome Sanger Institute and the Babraham Institute; and Astex, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Shionogi, Pfizer, Janssen R&D, Ferring, Eisai and Astellas.
The agreement is designed to facilitate the speedy exchange of reagents and information for research collaboration with academics across Cambridge. Projects may be established within a researcher’s own laboratories, or within the MTI’s Centre for Pathway Analysis. Each industry partner within the Milner Therapeutics Consortium has set aside funds for collaborative projects, which are open to any therapeutic area, and are expected to lead to joint publications.
The Annual Milner Therapeutics Symposium is an opportunity for scientists from academia and industry to discuss their latest research and its potential to be applied in pharm and biotech towards new treatments. Taking place annually in Cambridge for up to 400 delegates, it is the key networking event to foster collaborations with the Milner Therapeutic Alliance.
Registration to the annual symposium is free to academics, and available to all Miner-affiliated companies. The Milner Therapeutics Symposium 2022 takes place on Tuesday 28 June in Cambridge and online.